Database Surveillance Safety Study of PENTACEL® Vaccine
NCT00804284
Completed
The objective for this study is to characterize the safety profile of PENTACEL® vaccine for identification of potential vaccine-related adverse events not currently associated with PENTACEL® vaccine administration.
Gender:
MALE
Ages:
Between 6 weeks and 24 months
Trial Updated:
08/17/2015
Locations: Not set, Oakland, California
Conditions: Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae
Register for Updates
High Dose Influenza in Immunosuppressed Subjects
NCT00766285
Withdrawn
Influenza is a common infection of the upper airways and lungs, and is caused by viruses. Cancer patients may need a stronger influenza vaccine than the general population to protect against influenza. The experimental vaccine is designed to be 9 times stronger than the standard vaccine, which may cause a stronger immune response against influenza in patients with a weakened immune system. The goal of this study is to compare the effects of a new experimental influenza vaccine to the effects of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2015
Locations: The University of Texas - MD Anderson Cancer Center - Infectious Diseases, Houston, Texas
Conditions: Influenza
Register for Updates
Immune Memory After Papillomavirus Vaccination
NCT01505049
Completed
Vaccines for human papillomavirus (HPV) have been available in the United States since 2006. Early studies have shown a high rate of effectiveness of these vaccines, however it is not known how long this protection will last. The IMAP study will look at various parts of the immune system and potential markers for long lived immune responses to this vaccine.
Gender:
FEMALE
Ages:
Between 18 years and 30 years
Trial Updated:
07/20/2015
Locations: Emory University, Atlanta, Georgia
Conditions: Healthy Volunteers
Register for Updates
Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults
NCT00879814
Completed
The purpose of this study is to evaluate the safety and tolerability of an investigational meningococcal B rLP2086 vaccine in healthy adults.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
07/15/2015
Locations: Miami Research Associates, Inc., South Miami, Florida
Conditions: Meningitis, Meningococcal
Register for Updates
PPV: Pneumococcal Polysaccharide Vaccine in Older Adults
NCT00239694
Completed
The purpose of this study is to measure how long the improvement in the immune system lasts in older people after they have been vaccinated, and to examine the immune response in older people who get vaccinated a second time.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/14/2015
Locations: National Institute on Aging, Baltimore, Maryland
Conditions: Aging
Register for Updates
Study of Quadrivalent Influenza Vaccine Among Children
NCT01240746
Completed
The aim of the study is to evaluate a prototype quadrivalent influenza vaccine (QIV), the licensed 2010-2011 trivalent influenza vaccine (TIV) containing the primary B strain (B1), and the investigational TIV containing the alternate B (B2) strain in children. Primary Objective: To demonstrate non-inferiority of antibody responses to QIV compared with licensed 2010-2011 TIV (containing the primary B strain) and investigational TIV (containing the alternate B strain) as assessed by geometric me... Read More
Gender:
ALL
Ages:
Between 6 months and 8 years
Trial Updated:
06/16/2015
Locations: Not set, Dothan, Alabama +66 locations
Conditions: Influenza
Register for Updates
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
NCT00108732
Completed
Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. Androgens can cause the growth of prostate cancer cells. Drugs, such as bicalutamide and goserelin, may stop the adrenal glands from making androgens in patients whose tumor cells continue to grow. Giving vaccine therapy together with GM-CSF and, when needed, an... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/03/2015
Locations: Baptist Cancer Institute, Jacksonville, Florida +6 locations
Conditions: Recurrent Prostate Carcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Register for Updates
Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age
NCT01195571
Completed
The purpose of this research study is to test the safety and tolerability of four new investigational Cytomegalovirus (CMV) vaccines (Towne-Toledo 1, 2, 3, 4) in healthy male volunteers who are CMV negative. CMV is a common virus, infecting 50-80% of adults in the United States by the age of twenty-one. CMV does not usually cause illness in adults or children. However, CMV can be a cause of deafness and mental retardation in a child if a mother is infected during pregnancy. It also can be a seri... Read More
Gender:
MALE
Ages:
Between 30 years and 50 years
Trial Updated:
05/18/2015
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Cytomegalovirus
Register for Updates
Studies of the Immune Response to Vaccination After Hematopoietic Stem Cell Transplantation
NCT01581164
Completed
The purpose of this research study is to perform a serial analysis of immune function using blood cells and sera obtained from patients after vaccination following hematopoietic stem cell transplantation (HSCT). The focus of this study will be to characterize several immune parameters during the clinical course of HSCT and correlate these findings with the effect of vaccination.
Gender:
ALL
Ages:
Between 5 years and 70 years
Trial Updated:
05/07/2015
Locations: University of California, San Francisco, San Francisco, California
Conditions: Hematopoietic Stem Cell Transplant
Register for Updates
Phase 1 Norwalk Vaccine Study
NCT00806962
Completed
Randomized, double blind, multi-site, study in healthy adults, comparing safety and immunogenicity of two dosage levels of Norwalk VLP Vaccine with adjuvant/excipients and with placebo controls Primary Objective: * Safety as determined by occurrence of local intranasal symptoms or other symptoms as reported by a self-administered memory aid for 7 days after each vaccination and hematology, blood chemistry and physical examinations performed by the clinical research staff * Subjects will also b... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
05/05/2015
Locations: University of Maryland Center for Vaccine Development, Baltimore, Maryland +3 locations
Conditions: Norovirus
Register for Updates
Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer
NCT00020254
Completed
RATIONALE: Vaccines made from prostate cancer cells may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Interleukin-2 may stimulate a person's white blood cells to kill prostate cancer cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using nilutamide may fight prostate cancer by reducing the production of androgens. It is... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/28/2015
Locations: Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland
Conditions: Prostate Cancer
Register for Updates
Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus
NCT01023711
Completed
The purpose of this study is to describe the immune response to a novel H1N1 influenza vaccination in healthy adults, and to understand the factors that allow healthy adults to respond to a single dose of vaccine even if they have never previously experience novel H1N1 disease or vaccination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2015
Locations: Vaccine Research Unit Room 3-5000, Rochester, New York
Conditions: Influenza
Register for Updates